Role of resistin in cardiac contractility and hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 2, 2008, Pages 270-280

  Kim, Maengjo ^a   Oh, Jae kyun ^b   Sakata, Susumu ^c   Liang, Iifan ^a   Park, WooJin ^b   Hajjar, Roger J ^a   Lebeche, Djamel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Ca2+ transients; Cardiac hypertrophy; Contractility; Diabetes; Insulin resistance; IRS 1; MAP kinases; Resistin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCIUM ION; INSULIN RECEPTOR SUBSTRATE 1; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN BETA; RESISTIN; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART VENTRICLE HYPERTROPHY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROARRAY ANALYSIS; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SARCOMERE; STREPTOZOCIN DIABETES;

ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHENOTYPE; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RESISTIN;

ADENOVIRIDAE; RATTUS;

EID: 48849112002     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.05.006     Document Type: Article

References (50)

1. James P.T., Rigby N., and Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 11 1 (Feb 2004) 3-8
2. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 5 (May 2004) 1047-1053
3. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 347 5 (Aug 1 2002) 305-313
4. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 6818 (Jan 18 2001) 307-312
5. Rajala M.W., Lin Y., Ranalletta M., Yang X.M., Qian H., Gingerich R., et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 16 8 (Aug 2002) 1920-1930
6. Steppan C.M., and Lazar M.A. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13 1 (Jan-Feb 2002) 18-23
7. Ghosh S., Singh A.K., Aruna B., Mukhopadhyay S., and Ehtesham N.Z. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 305 1 (Feb 13 2003) 27-34
8. Burnett M.S., Devaney J.M., Adenika R.J., Lindsay R., and Howard B.V. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 91 1 (Jan 2006) 64-68
9. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88 12 (Dec 2003) 6098-6106
10. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., and DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28 6 (Jun 2004) 783-789
11. Lee J.H., Chan J.L., Yiannakouris N., Kontogianni M., Estrada E., Seip R., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88 10 (Oct 2003) 4848-4856
12. Heilbronn L.K., Rood J., Janderova L., Albu J.B., Kelley D.E., Ravussin E., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89 4 (Apr 2004) 1844-1848
13. Graveleau C., Zaha V.G., Mohajer A., Banerjee R.R., Dudley-Rucker N., Steppan C.M., et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 280 36 (Sep 9 2005) 31679-31685
14. Wang B.W., Hung H.F., Chang H., Kuan P., and Shyu K.G. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-alpha. Am J Physiol 293 4 (Oct 2007) H2305-2312
15. Rodrigues B., Cam M.C., Kong J., Goyal R.K., and McNeill J.H. Strain differences in susceptibility to streptozotocin-induced diabetes: effects on hypertriglyceridemia and cardiomyopathy. Cardiovasc Res 34 1 (Apr 1997) 199-205
16. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., and Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41 11 (Nov 1992) 1422-1428
17. Lebeche D., Kang Z.B., and Hajjar R. Candesartan abrogates G protein-coupled receptors agonist-induced MAPK activation and cardiac myocyte hypertrophy. J Renin-Angio-Aldo S 2 supplement 1 (2001) S154-1S61
18. Jeong D., Cha H., Kim E., Kang M., Yang D.K., Kim J.M., et al. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res 99 3 (Aug 4 2006) 307-314
19. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59 (1997) 551-571
20. Sugden P.H., and Clerk A. Regulation of mitogen-activated protein kinase cascades in the heart. Adv Enzyme Regul 38 (1998) 87-98
21. Ren J., and Davidoff A.J. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol 272 1 Pt 2 (Jan 1997) H148-158
22. Diabetes Atlas. International Diabetes Federation 2007; 3rd ed: http://www.eatlas.idf.org/media/.
23. Eckel R.H., Kahn R., Robertson R.M., and Rizza R.A. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 113 25 (Jun 27 2006) 2943-2946
24. Depre C., Young M.E., Ying J., Ahuja H.S., Han Q., Garza N., et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 32 6 (Jun 2000) 985-996
25. Dillmann W.H. Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes 29 7 (Jul 1980) 579-582
26. Molkentin J.D., and Dorn II I.G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
27. Lazar M.A. Resistin- and obesity-associated metabolic diseases. Horm Metab Res 39 10 (Oct 2007) 710-716
28. Kolter T., Uphues I., and Eckel J. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 273 1 Pt 1 (Jul 1997) E59-67
29. Shaw L.M. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 21 15 (Aug 2001) 5082-5093
30. Ouwens D.M., and Diamant M. Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy. Arch Physiol Biochem 113 2 (Apr 2007) 76-86
31. Withers D.J., and White M. Perspective: the insulin signaling system-a common link in the pathogenesis of type 2 diabetes. Endocrinology 141 6 (Jun 2000) 1917-1921
32. Gual P., Le Marchand-Brustel Y., and Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87 1 (Jan 2005) 99-109
33. Tzatsos A., and Kandror K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26 1 (Jan 2006) 63-76
34. Bouzakri K., Roques M., Gual P., Espinosa S., Guebre-Egziabher F., Riou J.P., et al. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52 6 (Jun 2003) 1319-1325
35. Tanti J.F., Gremeaux T., van Obberghen E., and Le Marchand-Brustel Y. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 269 8 (Feb 1994 25) 6051-6057
36. Ueno M., Carvalheira J.B., Tambascia R.C., Bezerra R.M., Amaral M.E., Carneiro E.M., et al. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48 3 (Mar 2005) 506-518
37. Kushiyama A., Shojima N., Ogihara T., Inukai K., Sakoda H., Fujishiro M., et al. Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. J Biol Chem 280 51 (Dec 23 2005) 42016-42025
38. Calabro P., Samudio I., Willerson J.T., and Yeh E.T. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110 21 (Nov 23 2004) 3335-3340
39. Rothwell S.E., Richards A.M., and Pemberton C.J. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 349 1 (Oct 13 2006) 400-407
40. Takeishi Y., Niizeki T., Arimoto T., Nozaki N., Hirono O., Nitobe J., et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J 71 4 (Apr 2007) 460-464
41. Lupattelli G., Marchesi S., Ronti T., Lombardini R., Bruscoli S., Bianchini R., et al. Endothelial dysfunction in vivo is related to monocyte resistin mRNA expression. J Clin Pharm Ther 32 4 (Aug 2007) 373-379
42. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., et al. The potential role of resistin in atherogenesis. Atherosclerosis 182 2 (Oct 2005) 241-248
43. Rajapurohitam V., Gan X.T., Kirshenbaum L.A., and Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 93 4 (Aug 22 2003) 277-279
44. Xu F.P., Chen M.S., Wang Y.Z., Yi Q., Lin S.B., Chen A.F., et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110 10 (Sep 7 2004) 1269-1275
45. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10 12 (Dec 2004) 1384-1389
46. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 1 (Apr 2 1999) 79-83
47. Matsubara M., Maruoka S., and Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87 6 (Jun 2002) 2764-2769
48. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 6 (Jun 2000) 1595-1599
49. Pellme F., Smith U., Funahashi T., Matsuzawa Y., Brekke H., Wiklund O., et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52 5 (May 2003) 1182-1186
50. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 5 (May 2001) 1930-1935